Breast cancer is characterised by uncontrolled growth of cells in the breast, causing lumps. The breast cancer diagnostic devices are used to diagnose cancer that occurs in the breasts. The main types of breast cancer diagnostics are imaging, biopsy, genomic tests, blood tests, and others. A biopsy is the process of removing a piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. The technologies involved is fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies. The cancer types involved are BRCA breast cancer, ER and PR breast cancer, her type 2-breast cancer, EGFR mutation test breast cancer, and others. The diagnostic types involved are ionising breast imaging technologies and non-ionizing imaging technologies. The end-users involved are hospitals and clinics, cancer research centers, diagnostic laboratories, and ambulatory surgical centers. The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global breast cancer diagnostics market grew from $4.06 billion in 2022 to $4.4 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The breast cancer diagnostics market is expected to grow from $5.86 billion in 2027 at a CAGR of 7.4%. The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for the breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. According to the World Health Organization (WHO), around 2.3 million women were diagnosed with breast cancer and 685,000 people died of breast cancer in 2020. Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market. The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer. The cost of diagnosis for breast cancer typically rose with the initiation of the diagnostic stage of the disease. According to HealthMatch, in 2020, the total cost of breast cancer treatment ranged between $20,000 and $100,000. The diagnosis alone ranged between $151 and $751 in various regions. Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market. Technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In September 2022, Niramai, an Indian Health-Tech company, launched an innovative solution called Thermalytix. It is a automated breast cancer screening and diagnostic tool which combines thermal imaging and AI. In January 2021, Hologic, a US-based women’s health medtech company, acquired Somatex Medical for $64 million. The acquisition would support Hologic’s strategy to provide comprehensive solutions for breast health care. Somatex is a German-based provider of Breast cancer diagnostic services. Major players in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., and C.R. Bard Inc. North America was the largest region in the breast cancer diagnostics market in 2022. Asia-Pacific was the second largest region in the global breast cancer diagnostics market. The regions covered in the global breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast cancer diagnostics market is segmented - 1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types 2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies 3) By Cancer Type: BRCA Breast Cancer, ER & PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types 4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies 5) By End Users: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Breast cancer drugs refer to anti-cancer medications that can be taken orally or intravenously (injected into a vein). The majority of the body's cancer cells are reached by the medications via the bloodstream. Chemotherapy may occasionally be administered directly into this region if cancer has spread to the spinal fluid, which surrounds and protects the brain and spinal cord (called intrathecal chemotherapy). The main drug types in breast cancer drugs are HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormonal receptors. A mitotic inhibitor is a medication that prevents cell division, or mitosis. These medications disrupt microtubules, which pull the chromosomes apart as a cell dividesetabolites, aromatase inhibitors, and hormonal receptors. A mitotic inhibitor is a medication that prevents cell division, or mitosis. These medications disrupt microtubules, which pull the chromosomes apart as a cell divides. The different types include metastatic breast cancer, triple-negative breast cancer, and others (ductal carcinoma in situ, invasive ductal carcinoma, inflammatory breast cancer, breast cancer during pregnancy, and others). The several sectors include hospitals, clinics, and others and are distributed through various channels, such as ambulatory surgical centers, hospitals, clinics, retail pharmacies, and online channels. The breast cancer drugs market research report is one of a series of new reports from The Business Research Company that provides breast cancer drugs market statistics, including breast cancer drugs industry global market size, regional shares, competitors with a breast cancer drugs market share, detailed breast cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer drugs industry. This breast cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global breast cancer drugs market size will grow from $31.50 billion in 2022 to $33.96 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global breast cancer drugs market size is expected to grow to $44.11 billion in 2027 at a CAGR of 6.8%. The increasing prevalence of breast cancer is driving the breast cancer drug market. Breast cancer is the most common type of cancer among women and affects around 2.1 million women each year. According to the World Health Organization, breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. The factors responsible for breast cancer include the heredity, age, and lifestyle of a person, and are more common in developed countries. As the number of people diagnosed with breast cancer rises, the demand for breast cancer drugs increases, thereby driving the market growth. Adverse side effects caused by the use of breast cancer drugs are acting as a restraint on the breast cancer drugs market. Breast cancer drugs can result in long-term or short-term side effects including headaches, dental issues, osteoporosis, heart problems, cataracts, blood clots, infertility, and others. As a result, patients depend on alternate or complementary treatments to deal with the side effects, thereby increasing overall treatment costs. Also, the long-lasting nature of some of the side effects discourages the use of breast cancer drugs, affecting the market growth. Manufacturers of breast cancer drugs are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For instance, AstraZeneca entered into a partnership deal worth $6.9 billion for the development of a breast cancer drug. According to the deal, the companies will jointly develop the drug trastuzumab deruxtecan and will share development and commercialization costs for the drug worldwide. Novartis collaborated with IBM Watson Health for the development of a solution that can determine drug combinations and sequences for the best patient outcomes. Manufacturers of breast cancer drugs are governed by various regulatory bodies, such as the Food and Drug Administration in the USA and the European Medicines Agency in the European Union. The European Medicines Agency (EMA) regulates the market for breast cancer drugs by granting licences to the drugs that have been proven to be safe and clinically effective. The drug is evaluated to understand its benefits and risks and then tested for any post-usage effects. The drug can be commercially sold in the European Union upon approval from the EMA. The EMA can also grant a conditional marketing authorization indicating approval but can withdraw it if found unsafe or ineffective. Major players in the breast cancer drugs market are F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca, Eli Lilly and Company, Celgene Corporation, Biocon, Merck & Co. Inc., Genzyme Corporation, Janssen Global Services LLC, and MacroGenics Inc. North America was the largest region in the breast cancer drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global breast cancer drugs market during the forecast period. The regions covered in the global breast cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The breast cancer drugs market consists of sales of Abemaciclib, Alpelisib, Anastrozole, and Aredia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast cancer drugs market is segmented - 1) By Type: Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others) 2) By Drug Type: HER2 Inhibitors, Mitotic Inhibitors, Anti-Metabolites, Aromatase Inhibitors, Hormonal Receptor 3) By End User: Ambulatory, Hospitals, Clinics, Other End-Users 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels

Breast cancer monoclonal antibodies (mAbs) refer to the use of antibodies in the treatment of both early-stage and advanced breast cancer. It functions by identifying and locating particular proteins on cancer cells. Every MAB recognises a different protein. Therefore, different MABs must be created to target various cancer types. They kill the cancer cell in various ways depending on the protein they are targeting. The main types of breast cancer monoclonal antibodies are naked mAbs and conjugated mAbs. Naked mAbs are antibodies that are free of any drugs or radioactive materials. They are self-contained. The most prevalent type of mAb used to fight cancer is this one. The different types of treatments include chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, and hormone therapy, and they are used in various sectors such as hospitals, and retail pharmacies. The breast cancer monoclonal antibodies (mAbs) market research report is one of a series of new reports from The Business Research Company that provides breast cancer monoclonal antibodies (mAbs) market statistics, including breast cancer monoclonal antibodies (mAbs) industry global market size, regional shares, competitors with a breast cancer monoclonal antibodies (mAbs) market share, detailed breast cancer monoclonal antibodies (mAbs) market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer monoclonal antibodies (mAbs) industry. This breast cancer monoclonal antibodies (mAbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global breast cancer monoclonal antibodies market grew from $16.67 billion in 2022 to $17.81 billion in 2023 at a compound annual growth rate (CAGR) of 6.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The breast cancer monoclonal antibodies market is expected to grow from $23.36 billion in 2027 at a CAGR of 7.0%. Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibody market’s growth. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. According to Breastcancer.org, a US-based non-profit organization, as of January 2020, there were more than 3.8 million women in the US with a history of breast cancer. This includes women who are currently being treated and women who have completed the treatment. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibody market. Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homoeopathic product market is projected to reach $18.6 billion by the end of 2027. The National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customise personalised vaccines. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market. Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. For instance, In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received a placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market. In November 2020, Merck & Co., Inc., a US-based research-oriented biopharmaceutical company, acquired VelosBio, Inc., for an amount of $2.75 billion. Through this acquisition, Merck will strengthen its oncology drug pipeline with VLS-101 for the treatment of patients with hematologic malignancies and solid tumours and its research capabilities in the field of cancer research. VelosBio, Inc. is a US-based clinical-stage biopharmaceutical company specialising in the development of brand-new antibody-drug conjugates ("ADCs") to treat solid tumours and hemological malignancies. Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma. North America was the largest region in the breast cancer monoclonal antibodies market in 2022. The regions covered in the global breast cancer monoclonal antibodies (mAbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer monoclonal antibodies (mAbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The breast cancer monoclonal antibodies (mAbs) market consists of sales of trastuzumab, pertuzumab, bevacizumab, and rituximab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast cancer monoclonal antibodies market is segmented - 1) By Product: Naked Mabs, Conjugated Mabs 2) By End-User: Hospitals, Retail Pharmacies 3) By Treatment: Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy

Breast implants are breast-shaped bags constructed of a silicone outer shell and filled with silicone gel or saline, and they used to change the size, shape, and form of the breasts. The main types of breast implants are silicone implant, form-stable implant, saline implant, and structured saline implant. The silicone implant is filled with silicone gel. The silicone gel has a similar texture to genuine breast tissue. They are used by hospital, cosmetology clinic, and other end users in breast augmentation and breast reconstruction procedures. The breast implants market research report is one of a series of new reports from The Business Research Company that provides breast implants market statistics, including breast implants industry global market size, regional shares, competitors with a breast implants market share, detailed breast implants market segments, market trends and opportunities, and any further data you may need to thrive in the breast implants industry. This breast implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global breast implants market size grew from $2.26 billion in 2022 to $2.43 billion in 2023 at a compound annual growth rate (CAGR) of 7.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The breast implants market size is expected to grow to $3.17 billion in 2027 at a CAGR of 6.9%. Growing breast cancer incidences significantly contributed to the growth of the breast implants market. Breast cancer is a type of cancer in which cells lining the breast lobules and ducts grow abnormally. Breast cancer surgery is a key component in breast cancer treatment, which involves removing of cancer through operations. The different procedures used in breast cancer treatment includes surgery to remove entire breast or portion of breast tissue or nearby lymph nodes or others. Breast implants are used by breast cancer patients after surgery to regain the breast shape and size and regains the natural body appearance. For instance, according to the study published in World Cancer Research Fund International, the total number of new breast cancer cases across the globe accounted for 2.2 million in 2020 and accounted for 12.5% all cancer cases in 2020. Therefore, the growing breast cancer incidences is expected to promote the growth of the breast implants market during forecast period. Lightweight breast implants are the key trends gaining popularity in the breast implants market. The lightweight breast implant (LWBI) is around 30% lighter than typical silicone implants while retaining the same size, shape, and function. The LWBI reduces weight-related problems and reoperation rates by lowering stress on breast tissues and preserving tissue reliability and integrity over time. For instance, in September 2020, POLYTECH Health & Aesthetics GmbH, a Germany-based manufacturer of breast implants launched an extended B-Lite line, the world's first and only lightweight breast implant. These implants are 30% lighter and possess advantages such as quicker recovery, less stretching from movement, greater daily comfort, and reduced post-operative pain. B-Lite with MESMO fine-texturing surface and B-Lite with the distinctive Microthane shell coating is among the new shapes and surfaces in the extended range. In May 2020, AbbVie Inc., a US-based biopharmaceutical company acquired Allergan for $63 billion. This acquisition broadens, diversifies, and enriches AbbVie's portfolio by adding long-term franchises in various appealing therapeutic areas, including immunology and neuroscience. Allergan PLC. is Ireland-based drugs and medical devices manufacturing company that manufactures breast implants. Major players in the breast implants market are Sientra Inc., GC Aesthetics, HansBioMed Corp., Establishment Labs S.A., Silimed, AbbVie Inc., Groupe Sebbin SAS, Polytech Health & Aesthetics, Cereplas, Laboratoires Arion, Mentor Worldwide LLC, Johnson & Johnson (Mentor Worldwide LLC), Guangzhou Wanhe Plastic Materials, and Ideal Implant. North America was the largest region in the breast implants market in 2022. The regions covered in the breast implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the breast implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The breast implants market consists of sales of Saline-Filled Breast Implants, Silicone-Filled Breast Implants, and Breast Tissue Expanders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast implants market is segmented - 1) By Type: Silicone Implant, Form-stable Implant, Saline Implant, Structured Saline Implant 2) By Procedure: Breast Augmentation, Breast Reconstruction 3) By End User: Hospital, Cosmetology Clinic, Other End Users

3D medical imaging is a cutting-edge optical imaging technology that produces enlarged images of the interior of the body for medical examination. 3D medical imaging is used to create three dimensions’ visual representation of interior body parts for medical analysis with the help of computer-aided design (CAD) or a magnetic resonance image (MRI). The main types in 3D medical imaging are ultrasound, X-ray, CT scan, and others. The x-rays are used to capture images that are 2D and create the illusion of 3D x-ray imaging. The various applications are gynecology and obstetrics, cardiology, neurology, orthopedics, and oncology that are used by various end-users such as diagnostic centres, hospitals, and research centres. The 3D medical imaging market research report is one of a series of new reports from The Business Research Company that provides 3D medical imaging market statistics, including 3D medical imaging industry global market size, regional shares, competitors with a 3D medical imaging market share, detailed 3D medical imaging market segments, market trends and opportunities, and any further data you may need to thrive in the 3D medical imaging industry. This 3D medical imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global 3D medical imaging devices market size will grow from $15.36 billion in 2022 to $16.27 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global 3D medical imaging devices market size is expected to grow to $20.45 billion in 2027 at a CAGR of 5.9%. Increasing cases of injuries such as sports-related injuries contribute to the growth of the 3D medical imaging market. The increase in sports-related injuries is due to the increasing participation of individuals in organized and unorganized sports activities. Moreover, the training of athletes with high strength and high load also results in more and more serious injuries. Sports injuries are mainly characterized by soft tissue injury. The use of 3D medical imaging devices such as ultrasound diagnosis, X-ray radiography, MRI imaging provides an accurate and objective basis for the diagnosis. The 3D medical imaging devices help in the examination of muscle fascia injury, tendon injury, ligament injury, meniscus injury, articular cartilage, and bone fracture. According to the Centre for the Disease Control and Prevention, it is estimated that there are 775,000 emergency room visits due to the injuries in children who are participating in unorganized and organized sports activities. Thus, the increase in demand for 3D medical imaging devices favors the market growth. The difficulties faced by the medical device industry owing to the COVID-19 outbreak such as the slowdown in orders and supply chain disruptions are likely to restraint the growth of the 3D medical imaging market over the next coming years. According to Medical Products Outsourcing (MPO) magazine published in April 2020, financial strains and supply chain disruptions are the major challenges faced by the medical devices industry. The manufacturers are experiencing a modest slowdown in orders attributed to tight management of inventories due to fear of the spread of the virus and slow pace of reorders owing to the impact of the virus on businesses. Moreover, the managers are also hesitant in overseeing the new product launches in uncertain times. This scenario is predicted to act as a major factor restraining the growth of the market shortly. 3D medical imaging device manufacturers are increasingly investing in Artificial Intelligence (AI) to improve the diagnosis by giving accurate, hard-number measurements. AI provides efficiency in medical imaging, particularly when it comes to detecting organs or anomalies. For instance, by combining image visualization and AI, cardiologists can measure ejection fraction with high precision and in a much shorter period. Ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts. For instance, In November 2021, GE Healthcare, a company operating in 3D imaging devices unveiled 60 innovative technology solutions including artificial intelligence to transform healthcare to help patients and clinicians with an effective way of solutions. In February 2020, Alphatec Holdings, Inc. (ATEC or the Company) acquired EOS imaging, SA for a purchase price of about $88 million. With this acquisition, ATEC will integrate spine imaging and anatomical modeling for better operative performance and is expected to significantly increase the demand for ATEC hardware and EOS systems. EOS Imaging is a France-based medical device company leading in orthopedic medical imaging solutions. Major players in the 3D medical imaging market are GE Healthcare, Royal Philips, Siemens AG, The Esaote Group, Intrasense SA, Materialize NV, Toshiba Group, Samsung Medison Co. Ltd., Shimadzu Corporation, and Analogic Corporation. Western Europe was the largest region in the 3D medical imaging market in 2022. Asia-Pacific was the second-largest region in the global 3D medical imaging devices market. The regions covered in the global 3D medical imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the 3D medical imaging market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The 3D medical imaging market consists of sales of ultrasound, magnetic resonance imaging (MRI), radiography, and computed tomography scan (CT). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global 3D medical imaging devices market is segmented - 1) By Type: Ultrasound, X-ray, CT Scan, Other Types 2) By End User: Diagnostic Centers, Hospitals, Research Centers 3) By Application: Gynecology and Obstetrics, Cardiology, Neurology, Orthopedics, Oncology

Cancer diagnostic devices are used to diagnose the stage and cause of the condition by identifying the oncogenic proteins, and certain enzymes released by the tumor cells in patients. The main products in cancer diagnostics are companion diagnostics and molecular diagnostics. Molecular diagnostics is a laboratory method that is used to check for certain proteins, genes, or other molecules that may be a sign of cancer. The methods used in cancer diagnostics are biopsy, endoscopy, tumor biomarker tests, and imaging. The applications covered in cancer diagnostics are cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others that are used by end-users such as cancer research institutes, diagnostic laboratories, hospitals, and others. The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cancer diagnostics market size will grow from $19.18 billion in 2022 to $21.38 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cancer diagnostics market size is expected to grow to $33.13 billion in 2027 at a CAGR of 11.6%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers are leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. The AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post market surveillance, and labeling requirements associated with their usage. For instance, the labeling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd., GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Illumina, Elekta AB, and C.R. BardInc. North America was the largest region in the cancer diagnostics market in 2022. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the global cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cancer diagnostics market is segmented - 1) By Products: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices